

## Corticosteroids with maintenance therapy

Do you generally administer dexamethasone in combination with the following agents for patients with MM who are receiving maintenance therapy?

	Bortezomib	Lenalidomide
Yes, for most patients	53%	44%
Yes, for select patients	18%	15%
No	29%	41%

### EDITOR'S COMMENTS

One of the most interesting and unexpected findings in this survey related to the use of corticosteroids as part of maintenance therapy. For patients receiving lenalidomide maintenance we found a split in corticosteroid use, with Dr Vij not using this strategy because he questions the rationale for adding the immunosuppressive effect of corticosteroids to an immunomodulatory agent and Dr Munshi adding corticosteroids to lenalidomide, citing a recent Italian trial that demonstrated a progression-free survival benefit with 50-mg prednisone administered 3 times a week, although he uses dexamethasone 10 to 20 mg weekly.

### SELECT REFERENCES WITH LINKS

Benboubker L et al. **Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.** *N Engl J Med* 2014;371(10):906-17. [Abstract](#)

Palumbo A et al. **A phase III study of ASCT vs cyclophosphamide-lenalidomide-dexamethasone and lenalidomide-prednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients.** *Proc ASH* 2013;[Abstract 763](#).